Esta página foi traduzida automaticamente e a precisão da tradução não é garantida. Por favor, consulte o versão em inglês para um texto fonte.

Effectiveness of Online Gut-Directed Hypnotherapy and Movement Motivational and Self-management Training for Abdominal Pain Disorders in Adolescents (HIPMO)

12 de novembro de 2026 atualizado por: János Major, Bethesda Children's Hospital

Effectiveness of Online Hypnotherapy and Movement Motivation Training for Abdominal Pain Disorders in Adolescents

The present study is an online-based investigation involving adolescents with abdominal pain disorders, defined as recurrent abdominal pain persisting for at least two months. The study aims to evaluate the feasibility, acceptability, and effectiveness of online therapeutic interventions in comparison with usual pediatric gastroenterological care.

The study has two primary objectives. The first is to make two therapeutic interventions-Movement Motivation and Self-management Training (M3 Training) and gut-directed hypnotherapy-available online in Hungarian to young people with abdominal pain disorders and their families. Providing these interventions in an online format may facilitate easier and more timely access to therapeutic support for adolescents experiencing abdominal symptoms.

The second objective is to evaluate the effectiveness of the two online interventions. Specifically, the effectiveness of M3 Training and gut-directed hypnotherapy will be assessed both as individual interventions and in combination, and compared with usual pediatric gastroenterological care. This evaluation will assess whether the online interventions, delivered individually or in combination, offer effective therapeutic options for adolescents with abdominal pain disorders, focusing on both primary and secondary outcomes.

Visão geral do estudo

Status

Ainda não está recrutando

Tipo de estudo

Intervencional

Inscrição (Estimado)

800

Estágio

  • Não aplicável

Contactos e Locais

Esta seção fornece os detalhes de contato para aqueles que conduzem o estudo e informações sobre onde este estudo está sendo realizado.

Contato de estudo

Locais de estudo

    • Budapest
      • Budapest, Budapest, Hungria, 1146
        • HRC Bethesda Children's Hospital
        • Subinvestigador:
          • Katalin Forgács-Kristóf, MSc
        • Contato:
        • Subinvestigador:
          • Adrienn Vargay, PhD
        • Subinvestigador:
          • Sára Bencsik, MD
        • Subinvestigador:
          • Nándor Hajdú, PhD
        • Subinvestigador:
          • Katalin Eszter Müller, MD, PhD

Critérios de participação

Os pesquisadores procuram pessoas que se encaixem em uma determinada descrição, chamada de critérios de elegibilidade. Alguns exemplos desses critérios são a condição geral de saúde de uma pessoa ou tratamentos anteriores.

Critérios de elegibilidade

Idades elegíveis para estudo

12 anos a 18 anos (Filho, Adulto)

Aceita Voluntários Saudáveis

Não

Gêneros Elegíveis para o Estudo

Tudo

Descrição

Inclusion Criteria:

Following the minimum diagnostic work-up performed by a gastroenterologist, including:

  • celiac disease serology;
  • C-reactive protein (CRP) or erythrocyte sedimentation rate (ESR);
  • complete blood count (CBC);
  • total protein;
  • albumin;
  • aspartate aminotransferase (AST; GOT);
  • alanine aminotransferase (ALT; GPT);
  • gamma-glutamyl transferase (GGT);
  • lactate dehydrogenase (LDH);
  • alkaline phosphatase (ALP);
  • urea;
  • creatinine;
  • iron studies;
  • urinalysis, at minimum using a urine dipstick;
  • fecal calprotectin or fecal occult blood testing.

Participants will be included in the study based on symptoms consistent with abdominal pain disorders according to the Rome V criteria and the following inclusion criteria:

  • Continuous or regularly recurrent abdominal pain persisting for at least 3 months.
  • No identifiable underlying organic disease that could explain the abdominal pain.
  • Able to care for themselves, capable of self-care and able to understand and follow the study procedures.
  • Able to read and write in Hungarian.
  • Has access to the internet.

Exclusion Criteria:

  • Known severe psychiatric disorder
  • Epilepsy
  • Gastrointestinal disease requiring treatment and associated with pain symptoms
  • Proctalgia fugax
  • Intellectual disability.

Plano de estudo

Esta seção fornece detalhes do plano de estudo, incluindo como o estudo é projetado e o que o estudo está medindo.

Como o estudo é projetado?

Detalhes do projeto

  • Finalidade Principal: Tratamento
  • Alocação: Randomizado
  • Modelo Intervencional: Atribuição Paralela
  • Mascaramento: Triplo

Armas e Intervenções

Grupo de Participantes / Braço
Intervenção / Tratamento
Sem intervenção: Standard care

In the standard care control group, as in the intervention groups, participants will use an online platform (hasifajdalomkezeles.hu) to record their adherence to the treatment recommended by their gastroenterologist. The website does not include any therapeutic videos or active intervention. Its sole function is to support repeated online questionnaire-based data collection assessing treatment fidelity, adherence, and perceived effectiveness of the treatment.

The primary and secondary outcome questionnaires become available at predefined time points over a 12-week period.

Experimental: Gut-Focused Hypnosis Program

The hypnosis arm is delivered through the same main study website (hasifajdalomkezeles.hu), presenting content developed based on the Dutch model of gut-directed hypnosis (www.hypnosis4abdominalpain.com), adapted with permission to Hungarian. The program is primarily based on video and audio materials and follows a predefined, standardised structure.

The 12-week-long intervention content has a linear format consisting of sequential modules that introduce: the concept of abdominal pain disorders; the development of bowel hypersensitivity; the principles of medical hypnosis; and the role of hypnosis in the treatment of abdominal pain.

This section is accompanied by weekly audio-based exercises that are designed to align with the original Dutch model. Adolescents are encouraged to complete the exercises that correspond to the weekly audio sessions, promoting deeper engagement and understanding of the material.

The hypnosis website is non-adaptive and non-personalised.

The hypnosis arm is delivered through the same main study website (hasifajdalomkezeles.hu), presenting content developed based on the Dutch model of gut-directed hypnosis ( www.hypnosis4abdominalpain.com), adapted with permission to Hungarian. The program is primarily based on video and audio materials and follows a predefined, standardised structure.

The 12-week-long intervention content has a linear format consisting of sequential modules that introduce: the concept of abdominal pain disorders; the development of bowel hypersensitivity; the principles of medical hypnosis; and the role of hypnosis in the treatment of abdominal pain.

This section is accompanied by weekly audio-based exercises that are designed to align with the original Dutch model. Adolescents are encouraged to complete the exercises that correspond to the weekly audio sessions, promoting deeper engagement and understanding of the material.

The hypnosis website is non-adaptive and non-personalised.

Experimental: M3 Training

M3 Training is a fully digitalised, 12-week online movement-motivation program delivered through the same website (hasifajdalomkezeles.hu). The previously developed and tested M3 Training program is fully adapted for digital delivery, with content specifically designed to support young people with chronic abdominal pain in developing their own movement program.

During the first two weeks, the video series guides participants through the process of designing an individually developed movement program, which they then carry out over 3 months. From weeks 3 to 12, participants receive ongoing motivational videos and supporting materials aimed at maintaining engagement and supporting implementation of their movement plan. Throughout this period, participants are able to modify and further develop their movement program.

Participants provide written responses to questions linked to the videos through the website, allowing them to reflect on their experiences and development throughout.

M3 Training is a fully digitalised, 12-week online movement-motivation program delivered through the same website (fasifajdalomkezeles.hu). The previously developed and tested M3 Training program is fully adapted for digital delivery, with content specifically designed to support young people with chronic abdominal pain in developing their own movement program.

During the first two weeks, the video series guides participants through the process of designing an individually developed movement program, which they then carry out over 3 months. From weeks 3 to 12, participants receive ongoing motivational videos and supporting materials aimed at maintaining engagement and supporting implementation of their movement plan. Throughout this period, participants are able to modify and further develop their movement program.

Participants provide written responses to questions linked to the videos through the website, allowing them to reflect on their experiences and development throughout.

Experimental: Combined Hypnosis + M3 Training

This arm represents an integrated version of the hypnosis program and M3 Training, combining the two existing interventions into a single 12-week online program. Users access both therapeutic components through the same website (hasifajdalomkezeles.hu). During the 12-week-long joint program the hypnosis-related content and the M3 Training videos are released according to a coordinated schedule. The aim is not simply to provide the two interventions in parallel, but to achieve structured integration, ensuring that the two approaches complement one another.

The hypnosis arm is delivered through the same main study website (hasifajdalomkezeles.hu), presenting content developed based on the Dutch model of gut-directed hypnosis ( www.hypnosis4abdominalpain.com), adapted with permission to Hungarian. The program is primarily based on video and audio materials and follows a predefined, standardised structure.

The 12-week-long intervention content has a linear format consisting of sequential modules that introduce: the concept of abdominal pain disorders; the development of bowel hypersensitivity; the principles of medical hypnosis; and the role of hypnosis in the treatment of abdominal pain.

This section is accompanied by weekly audio-based exercises that are designed to align with the original Dutch model. Adolescents are encouraged to complete the exercises that correspond to the weekly audio sessions, promoting deeper engagement and understanding of the material.

The hypnosis website is non-adaptive and non-personalised.

M3 Training is a fully digitalised, 12-week online movement-motivation program delivered through the same website (fasifajdalomkezeles.hu). The previously developed and tested M3 Training program is fully adapted for digital delivery, with content specifically designed to support young people with chronic abdominal pain in developing their own movement program.

During the first two weeks, the video series guides participants through the process of designing an individually developed movement program, which they then carry out over 3 months. From weeks 3 to 12, participants receive ongoing motivational videos and supporting materials aimed at maintaining engagement and supporting implementation of their movement plan. Throughout this period, participants are able to modify and further develop their movement program.

Participants provide written responses to questions linked to the videos through the website, allowing them to reflect on their experiences and development throughout.

O que o estudo está medindo?

Medidas de resultados primários

Medida de resultado
Descrição da medida
Prazo
Pain intensity (proportion of patients with ≥30% improvement in abdominal pain) measured by Numerical Rating Scale
Prazo: From enrollment to the end of treatment at 12 weeks.

≥30% reduction in pain intensity is our main outcome. Pain intensity will be assessed using an 11-point Numerical Rating Scale (NRS; 0-10), which is a validated measure of self-reported pain intensity in children and adolescents (Miró et al., 2009).

From enrollment to the end of treatment at 12 weeks.
Quality of Life measured by The Pediatric Quality of Life Inventory
Prazo: From enrollment to the end of treatment at 12 weeks

The Pediatric Quality of Life Inventory (PedsQL) is a validated questionnaire designed to assess health-related quality of life in children and adolescents.

From enrollment to the end of treatment at 12 weeks

Medidas de resultados secundários

Medida de resultado
Descrição da medida
Prazo
Functional Disability assessed by Functional Disability Inventory
Prazo: From enrollment to the end of treatment at 12 weeks

The Functional Disability Inventory (FDI) is a 15-item self-report measure assessing limitations in everyday physical, social, and school-related activities. It has been extensively validated in children and adolescents, including a large sample of 596 patients aged 8-17 years with chronic abdominal pain (Walker & Greene, 1991; Claar & Walker, 2006). Both the child and parent versions of the questionnaire will be administered.

From enrollment to the end of treatment at 12 weeks
Anxiety and Depression measured by Revised Children's Anxiety and Depression Scale (RCADS)
Prazo: From enrollment to the end of treatment at 12 weeks

The Revised Children's Anxiety and Depression Scale (RCADS) is a 47-item self-report questionnaire assessing symptoms of anxiety and depression in children and adolescents and has demonstrated good psychometric properties in both community and clinical populations (Chorpita et al., 2000; Chorpita et al., 2005). Both the child and parent versions of the questionnaire will be administered.

From enrollment to the end of treatment at 12 weeks
Gastrointestinal symptom-specific anxiety measured by Visceral Sensitivity Index
Prazo: From enrollment to the end of treatment at 12 weeks

The original Visceral Sensitivity Index (VSI) is a 15-item, unidimensional self-report questionnaire developed to assess gastrointestinal symptom-specific anxiety-that is, anxiety, worry, and fear related to gastrointestinal sensations, symptoms, and the situations in which these symptoms may occur. It was developed and validated in 96 adult patients with irritable bowel syndrome (IBS) and showed excellent reliability together with good content, convergent, divergent, and predictive validity (Labus et al., 2004). Both the child and parent versions of the questionnaire will be administered.

From enrollment to the end of treatment at 12 weeks
Different cognitive, behavioural, and interpersonal strategies used by children to cope with pain assessed by Pain Coping Questionnaire
Prazo: From enrollment to the end of treatment at 12 weeks

The Pain Coping Questionnaire (PCQ) is a 39-item self-report measure assessing different cognitive, behavioural, and interpersonal strategies used by children to cope with pain. It was developed for children and adolescents and has been validated from approximately 8 years of age, including populations with recurrent pain (Reid et al., 1998). Both the child and parent versions of the questionnaire will be administered.

From enrollment to the end of treatment at 12 weeks
Missing school days collected from parents
Prazo: From enrollment to the end of treatment at 12 weeks

School absence will be assessed as the parent-reported number of school days missed because of abdominal pain or gastrointestinal symptoms during a predefined recall period. Both the child and parent versions of the questionnaire will be administered.

From enrollment to the end of treatment at 12 weeks
Sleep characteristics assessed using study-specific self-report items
Prazo: From enrollment to the end of treatment at 12 weeks

Sleep characteristics will be assessed using study-specific self-report items covering perceived sleep quality, average nightly sleep duration, and frequency of daytime naps.

From enrollment to the end of treatment at 12 weeks
Intervention Satisfaction and Patient Global Impression of Change assessed by open-ended question
Prazo: From enrollment to the end of treatment at 12 weeks

Patient satisfaction will be explored using the following open-ended question: "What story would you tell your best friend about your experience with the therapy over the past 12 weeks?"

Patient Global Impression of Change will be measured through the following question:

Since the start of the study, my overall status is: options range from "Very Much Improved" to "Very Much Worse" Both the child and parent versions of the questionnaire will be administered.

From enrollment to the end of treatment at 12 weeks
Website engagement collected via webpage
Prazo: From enrollment to the end of treatment at 12 weeks

Website monitoring will include the number and timing of logins, the duration and frequency of listening to the audio recordings, the duration and frequency of viewing the M3 videos, whether each audio recording was listened to at least once, whether each video was viewed at least once, and whether all questions were answered; if not, the number and identity of unanswered questions will also be recorded.

From enrollment to the end of treatment at 12 weeks
Adequate Relief of Abdominal Pain and/or Discomfort assessed using a single dichotomous (yes/no) question.
Prazo: From enrollment to the end of treatment at 12 weeks

Proportion of participants reporting adequate relief of abdominal pain and/or discomfort during the preceding week compared with baseline, assessed using a single dichotomous (yes/no) question.

From enrollment to the end of treatment at 12 weeks

Outras medidas de resultado

Medida de resultado
Descrição da medida
Prazo
Adverse event assessed by open-ended questions
Prazo: From enrollment to the end of treatment at 12 weeks

Adverse events will be monitored prospectively throughout the intervention period. An adverse event will be defined as any new or worsening unfavourable physical or psychological health-related occurrence during study participation, irrespective of whether it is considered to be related to the intervention. At each scheduled assessment, participants will be asked about any new or worsening health-related problems since the previous assessment. If an adverse event is reported, a brief description of the event, its impact on daily activities, whether medical attention was required, and whether it resulted in modification or discontinuation of the intervention will be recorded. Reported events will subsequently be reviewed by the study team with respect to severity, seriousness, expectedness, and possible relatedness to the intervention (Junqueira et al., 2023; Burns et al., 2024). Both the child and parent versions of the questionnaire will be administered.

From enrollment to the end of treatment at 12 weeks

Colaboradores e Investigadores

É aqui que você encontrará pessoas e organizações envolvidas com este estudo.

Publicações e links úteis

A pessoa responsável por inserir informações sobre o estudo fornece voluntariamente essas publicações. Estes podem ser sobre qualquer coisa relacionada ao estudo.

Links úteis

Datas de registro do estudo

Essas datas acompanham o progresso do registro do estudo e os envios de resumo dos resultados para ClinicalTrials.gov. Os registros do estudo e os resultados relatados são revisados ​​pela National Library of Medicine (NLM) para garantir que atendam aos padrões específicos de controle de qualidade antes de serem publicados no site público.

Datas Principais do Estudo

Início do estudo (Estimado)

1 de dezembro de 2026

Conclusão Primária (Estimado)

1 de dezembro de 2030

Conclusão do estudo (Estimado)

1 de dezembro de 2030

Datas de inscrição no estudo

Enviado pela primeira vez

12 de novembro de 2026

Enviado pela primeira vez que atendeu aos critérios de CQ

12 de novembro de 2026

Primeira postagem (Real)

18 de novembro de 2026

Atualizações de registro de estudo

Última Atualização Postada (Real)

18 de novembro de 2026

Última atualização enviada que atendeu aos critérios de controle de qualidade

12 de novembro de 2026

Última verificação

1 de novembro de 2026

Mais Informações

Termos relacionados a este estudo

Termos MeSH relevantes adicionais

Outros números de identificação do estudo

  • BM/9151-1/2024

Plano para dados de participantes individuais (IPD)

Planeja compartilhar dados de participantes individuais (IPD)?

NÃO

Informações sobre medicamentos e dispositivos, documentos de estudo

Estuda um medicamento regulamentado pela FDA dos EUA

Não

Estuda um produto de dispositivo regulamentado pela FDA dos EUA

Não

Essas informações foram obtidas diretamente do site clinicaltrials.gov sem nenhuma alteração. Se você tiver alguma solicitação para alterar, remover ou atualizar os detalhes do seu estudo, entre em contato com register@clinicaltrials.gov. Assim que uma alteração for implementada em clinicaltrials.gov, ela também será atualizada automaticamente em nosso site .

Se inscrever